Why The Vaccine Oil Rally Won't Last By Irina Slav - Nov

New Post Public Reply Private Reply Replies (0) Message Board
SaltyMutt
160
Why The Vaccine Oil Rally Won't Last

By Irina Slav - Nov 24, 2020

2020-11-24_oexs6db0yp.jpg

Oil is on the rise after a third company developing a vaccine for Covid-19 announced positive efficacy results this week. They may well continue to rise for a while, but it would pay to be careful with betting on an endless rally. Yesterday, after AstraZeneca said its vaccine candidate had 90% efficacy in some cases, oil benchmarks jumped to the highest in three months as traders rushed to build their positions ahead of the rebound that should logically follow a successful vaccination campaign.

Fund managers also went on a buying spree, Reuters’s John Kemp said in his weekly column. The total purchases made in the most traded crude oil and product contracts over the last two weeks reached 539 million barrels, Kemp noted, which was the highest since the start of September.

The buying spree is not limited to oil, either, and analysts are taking note. The Bank of America last Friday said traders have swarmed into riskier assets after the two vaccine updates from Moderna and Pfizer, pouring $27 billion in to equity funds and shares in the industries that were worst affected by the pandemic, including energy, banking, and travel.

But the bank cautioned against too much optimism: “We say credit and equity prices (are) to peak in coming months on peak positioning, peak policy, peak profits as optimism tops ahead of vaccine distribution,” the analysts told BofA clients.

Related: Saudi Aramco’s Landmark IPO Is Costing The Kingdom Billions
Indeed, the higher oil—and stock—prices rise on this vaccine-prompted bullishness, the more vulnerable they become to a correction. Reuters’ Kemp noted this in his column, and bank analysts have warned about it in notes to clients.

The problem seems to be that traders are buying the vaccine efficacy news, but efficacy—and safety—is only the beginning. Swift distribution is another major aspect of a vaccine’s success, and the scale of vaccinations is another. The process, which the head of the U.S. federal government’s vaccination program said could begin in early December, would take at least several months until vaccinations are mass enough to make a difference to the so-called new normal.

In other words, it will be at least several months before oil demand picks up in a way that would be meaningful for prices over a period longer than 24 hours. That is, of course, if there are no serious side effects from the approved vaccines that could wreak a whole new kind of havoc on oil—and other—markets.

Meanwhile, OPEC+ is contributing to the bullish sentiment by signaling it would extend its current rate of production cuts into 2021, although it remains to be decided how long the extension will be. The cartel is meeting next Monday and Tuesday to discuss the issue.

Related: EIA Sees WTI Crude Averaging $44 In 2021


News from China is also supporting prices this week: Bloomberg reported the country has started drawing down its oil inventories as domestic demand picks up and imports decline because independent refiners have used up most of their import quotas. China’s inventories were a cause for concern among oil traders when they were running near capacity, so the news of a drawdown has been welcome.

Right now, the going is good for oil. Pharma companies are bound to continue providing updates, and these are more likely than not to be positive. The rally could last a week or two if OPEC+ decides on an extension of more than three months. But it will likely come to an end when traders get a reality check, which is bound to happen. Air travel will not return to pre-pandemic levels overnight. It won’t return to normal over a fortnight, either. It will take months.

The sooner market players accept this fact, the less likely a major oil price slump caused by spooked traders would be.

By Irina Slav for Oilprice.com

https://oilprice.com/Energy/Oil-Prices/Why-Th...-Last.html
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

From 10 Years to 40: Toyota’s Bet on the Future of EV Batteries

Updated Category Investing Views 22

For much of the past decade, no car company was as indecisive as Toyota. Tesla made the news, BYD grew faster than anyone anticipated, and traditional European brands tried to electrify everything in sight. First, it relied on hybrids; second, it largely kept its work on the solid-state battery under wraps; and finally, it waited and watched. Some even called Toyota...

Continue Reading
Morgan Stanley Elevates 173 Employees to Managing Directors

Updated Category News Views 338

Morgan Stanley Reaches New Heights with Employee Promotions Morgan Stanley (NYSE: MS), one of Wall Street's well-known banking institutions, has taken a notable step by promoting 173 employees to the prestigious position of managing director. This increase highlights the firm's commitment to internal growth and talent recognition, representing a 12% rise in these...

Continue Reading
Andersen Launches Institute for Global Finance and Economics

Updated Category News Views 115

Introducing the Andersen Institute for Finance and Economics Global professional services firm Andersen has taken an ambitious step by launching the Andersen Institute for Finance & Economics. This groundbreaking initiative will be guided by the expertise of Fabio Natalucci, who is determined to delve into the major global trends that are impacting economies, financial...

Continue Reading
TeleSpecialists Achieves Milestone in Telemedicine Accreditation

Updated Category News Views 215

TeleSpecialists Sets New Benchmark with NCQA Reaccreditation This accomplishment highlights the commitment of TeleSpecialists to excellence in patient care and credentialing. TeleSpecialists, renowned for its expertise in TeleStroke, TeleNeurology, and TelePsychiatry solutions, has made headlines with a perfect score on its National Committee for Quality Assurance (NCQA)...

Continue Reading
DOAR and John Jay College Unite to Enhance Trial Consulting Practices

Updated Category News Views 131

DOAR's Enhanced Collaboration with John Jay College In a significant step forward, DOAR, a prominent trial consulting firm, has unveiled an expanded partnership with John Jay College of Criminal Justice. This collaboration aims to redefine and elevate the practice of trial strategy consulting. DOAR has long been a supporter of John Jay's graduate programs, including the...

Continue Reading